The cohydrolases in human spleen that stimulate glucosyl ceramide [beta]-glucosidase

A family of [beta]-glucosidase-stimulating proteins (called cohydrolase SPH-I here) was isolated from bovine, Gaucher human and control human spleens. All preparations exhibited a similar pattern of four major electrophoretic bands in polyacrylamide when stained with the cationic dye, Stains-All. The bovine bands migrated more rapidly, while the two types of human cohydrolase migrate very similarly. The two human preparations differend in several respects: the concentration was much higher in Gaucher spleen; the Gaucher factors eluted a little earlier from gel permeation and decyl agarose columns; much more of the cohydrolase was bound by a concanavalin A column; the control bands stained less in gels than the Gaucher bands. Antibodies raised in rabbits to bovine cohydrolase reacted with all three preparations. All four bands evident that the cohydrolases from control and Gaucher spleens are similar in many respects, yet differ in some secondary fashion, possibly in carbohydrate content. It is suggested that Gaucher cohydrolase is formed from normal cohydrolase by the nonenzymatic action of cellular glucose over a period of many years, due to slowed catabolism of the cofactor.Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/25084/1/0000515.pd

UTM UAS Service Supplier Development: Sprint 2 Toward Technical Capability Level 4

NASA's UAS Traffic Management (UTM) Project has been tasked with developing concepts and initial implementations for integrating and managing small unmanned aircraft systems (UAS) into the low altitude airspace. To accomplish this task, the UTM Project planned a phased approach based on four Technical Capability Levels (TCLs). As of this writing, TCL4 is currently in development for a late Spring 2019 flight demonstration. This TCL is focused on operations in an urban environment and includes the handling of high density environments, large-scale off-nominal conditions, vehicle-to-vehicle communications, detect-and-avoid technologies, communication requirements, public safety operations, airspace restrictions, and other related goals. Through research and testing to date, NASA has developed an architecture for UTM that depends on commercial entities collaboratively providing services that are traditionally provided by the Air Navigation Service Provider (ANSP) in manned aviation. A key component of this architecture is the UAS Service Supplier (USS), which acts as a communications bridge between UAS operators and the ANSP when necessary. In addition, the collection of USSs form a USS Network to collaboratively manage the airspace through the sharing of data and the adherence to a standard or set of standards required to participate in this USS Network. This document provides a record of the second of four planned steps in the development of interoperable USSs that will ultimately support TCL4 flight testing and formalization of the overall UTM concept. To develop these USSs and their underlying specifications, NASA has planned a series of "Sprints" to work with industry partners in implementing the features and develop proposed specifications for USSs in order to to participate in TCL4. This report describes Sprint Two. In this Sprint, there was a major theme with four goals. The theme was the development and testing of a new USS discovery system, to better enable USSs to find and communicate with each other. The goals supporting this theme were: participants needed to implement and exercise the discovery service for USS-USS communications; USSs needed to demonstrate strategic deconfliction through operation sharing; the systems were to use discovery to aid in handling off-nominal operations; and finally, there was an investigation of an initial off-nominal reporting capability

UTM UAS Serivce Supplier Development: Sprint 1 Toward Technical Capability Level 4

NASA's UAS Traffic Management (UTM) Project has been tasked with developing concepts and initial implementations for integrating and managing small unmanned aircraft systems (UAS) into the low altitude airspace. To accomplish this task, the Project planned a phased approach based on four Technical Capability Levels (TCLs). As of this writing, TCL4 is currently in development for a late Spring 2019 flight demonstration. This TCL is focused on operations in an urban environment and includes the handling of high density and large-scale off-nominal conditions, vehicle-to-vehicle communications, detect-and-avoid technologies, communication requirements, public safety operations, airspace restrictions, and other related goals. Through research and testing to date, NASA has developed an architecture for UTM that depends on commercial entities collaboratively providing services that are traditionally provided by the Air Navigation Service Provider(ANSP) in manned aviation. A key component of this architecture is the UAS Service Supplier (USS), which acts as a communications bridge between UAS operators and the ANSP when necessary. In addition, the collection of USSs form a USS Network to collaboratively manage the airspace through the sharing of data and the adherence to a standard or set of standards required to participate in this USS Network. This document provides a record of the first step in the development of interoperable USSs that will ultimately support TCL4 flight testing and formalization of the overall UTM concept. To develop these USSs and the underlying specifications for them, NASA has planned a series of "Sprints" to work with industry partners in implementing the features and proposed specifications for USSs to participate in TCL4. This report describes Sprint One. In this Sprint, the focus was on establishing a baseline for the Application Programming Interfaces (APIs) and their associated data models. In addition, the concept of UAS Volume Reservations (UVR) (areas that impose restrictions on sUAS that are allowed to operate) was tested. NASA provided the specifications and iterated on them with partners while implementers developed to those specifications. NASA then tested each partner's implementation to ensure compatibility with all other implementers. This process helped all stakeholders gain confidence that the foundation for future Sprints was solid

Improved Procedures for Purification of the Bandeiraea simplicifolia I Isolectins and Bandeiraea simplicifolia II Lectin by Affinity Chromatography

Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/66350/1/j.1432-1033.1980.tb07197.x.pd

Mast Cells in Stress, Pain, Blood-Brain Barrier, Neuroinflammation and Alzheimer’s Disease

Mast cell activation plays an important role in stress-mediated disease pathogenesis. Chronic stress cause or exacerbate aging and age-dependent neurodegenerative diseases. The severity of inflammatory diseases is worsened by the stress. Mast cell activation-dependent inflammatory mediators augment stress associated pain and neuroinflammation. Stress is the second most common trigger of headache due to mast cell activation. Alzheimer’s disease (AD) is a progressive irreversible neurodegenerative disease that affects more women than men and woman’s increased susceptibility to chronic stress could increase the risk for AD. Modern life-related stress, social stress, isolation stress, restraint stress, early life stress are associated with an increased level of neurotoxic beta amyloid (Aβ) peptide. Stress increases cognitive dysfunction, generates amyloid precursor protein (APP), hyperphosphorylated tau, neurofibrillary tangles (NFTs), and amyloid plaques (APs) in the brain. Stress-induced Aβ persists for years and generates APs even several years after the stress exposure. Stress activates hypothalamic-pituitary adrenal (HPA) axis and releases corticotropin-releasing hormone (CRH) from hypothalamus and in peripheral system, which increases the formation of Aβ, tau hyperphosphorylation, and blood-brain barrier (BBB) disruption in the brain. Mast cells are implicated in nociception and pain. Mast cells are the source and target of CRH and other neuropeptides that mediate neuroinflammation. Microglia express receptor for CRH that mediate neurodegeneration in AD. However, the exact mechanisms of how stress-mediated mast cell activation contribute to the pathogenesis of AD remains elusive. This mini-review highlights the possible role of stress and mast cell activation in neuroinflammation, BBB, and tight junction disruption and AD pathogenesis

CD1d-restricted pathways in hepatocytes control local natural killer T cell homeostasis and hepatic inflammation

Invariant natural killer T (iNKT) cells recognize lipid antigens presented by CD1d and play a central role in regulating immunity and inflammation in peripheral tissues. However, the mechanisms which govern iNKT cell homeostasis after thymic emigration are incompletely understood. Here we demonstrate that microsomal triglyceride transfer protein (MTP), a protein involved in the transfer of lipids onto CD1d, regulates liver iNKT cell homeostasis in a manner dependent on hepatocyte CD1d. Mice with hepatocyte-specific loss of MTP exhibit defects in the function of CD1d and show increased hepatic iNKT cell numbers as a consequence of altered iNKT cell apoptosis. Similar findings were made in mice with hepatocyte-specific loss of CD1d confirming a critical role of CD1d in this process. Moreover, increased hepatic iNKT cell abundance in the absence of MTP is associated with susceptibility to severe iNKT cell-mediated hepatitis thus demonstrating the importance of CD1d-dependent control of liver iNKT cells in maintaining immunological homeostasis in the liver. Together, these data demonstrate an unanticipated role of parenchymal cells, as shown here for hepatocytes, in tissue-specific regulation of CD1d-restricted immunity and further suggest that alterations in lipid metabolism may affect iNKT cell homeostasis through effects on CD1d-associated lipid antigens.Work was supported by: The Deutsche Forschungsgemeinschaft (DFG) (ZE814/5-1), the European Research Council (ERC Starting Grant agreement n°336528), the Crohn’s and Colitis Foundation of America (Postdoctoral Fellowship Award), the European Commission (Marie Curie International Reintegration Grant n°256363), and the DFG Excellence Clusters “Inflammation at Interfaces” and “Center for Regenerative Therapies ” (S.Z.) and NIH grants DK044319, DK051362, DK053056, DK088199 and the Harvard Digestive Diseases Center (HDDC) (DK0034854) (R.S.B.)

Akt-mTORC1 signaling regulates Acly to integrate metabolic input to control of macrophage activation

Macrophage activation/polarization to distinct functional states is critically supported by metabolic shifts. How polarizing signals coordinate metabolic and functional reprogramming, and the potential implications for control of macrophage activation, remains poorly understood. Here we show that IL-4 signaling co-opts the Akt-mTORC1 pathway to regulate Acly, a key enzyme in Ac-CoA synthesis, leading to increased histone acetylation and M2 gene induction. Only a subset of M2 genes is controlled in this way, including those regulating cellular proliferation and chemokine production. Moreover, metabolic signals impinge on the Akt-mTORC1 axis for such control of M2 activation. We propose that Akt-mTORC1 signaling calibrates metabolic state to energetically demanding aspects of M2 activation, which may define a new role for metabolism in supporting macrophage activation

Chromosomal microarray testing in adults with intellectual disability presenting with comorbid psychiatric disorders.

Chromosomal copy-number variations (CNVs) are a class of genetic variants highly implicated in the aetiology of neurodevelopmental disorders, including intellectual disabilities (ID), schizophrenia and autism spectrum disorders (ASD). Yet the majority of adults with idiopathic ID presenting to psychiatric services have not been tested for CNVs. We undertook genome-wide chromosomal microarray analysis (CMA) of 202 adults with idiopathic ID recruited from community and in-patient ID psychiatry services across England. CNV pathogenicity was assessed using standard clinical diagnostic methods and participants underwent comprehensive medical and psychiatric phenotyping. We found an 11% yield of likely pathogenic CNVs (22/202). CNVs at recurrent loci, including the 15q11-q13 and 16p11.2-p13.11 regions were most frequently observed. We observed an increased frequency of 16p11.2 duplications compared with those reported in single-disorder cohorts. CNVs were also identified in genes known to effect neurodevelopment, namely NRXN1 and GRIN2B. Furthermore deletions at 2q13, 12q21.2-21.31 and 19q13.32, and duplications at 4p16.3, 13q32.3-33.3 and Xq24-25 were observed. Routine CMA in ID psychiatry could uncover ~11% new genetic diagnoses with potential implications for patient management. We advocate greater consideration of CMA in the assessment of adults with idiopathic ID presenting to psychiatry services